Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis

Leonard Amaral, J. Molnár

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible. This article will describe the authors' further work and the mechanisms by which thioridazine alone and in combination with antibiotics cures an extensively drug-resistant infection and why it is expected to cure totally drug-resistant TB infections as well. The concepts presented are entirely new and because they focus on the activation of killing by nonkilling macrophages where M. tuberculosis normally resides during infection, and coupled to the inhibition of efflux pumps which contribute to the antibiotic-resistant status, effective therapy of any antibiotic-resistant TB infection is possible.

Original languageEnglish
Pages (from-to)869-873
Number of pages5
JournalExpert Review of Anti-Infective Therapy
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 2012

Fingerprint

Thioridazine
Multidrug-Resistant Tuberculosis
Anti-Bacterial Agents
Infection
Mycobacterium tuberculosis
Tuberculosis
Microbial Drug Resistance
Antipsychotic Agents
Macrophages
Therapeutics
Pharmaceutical Preparations

Keywords

  • efflux pumps
  • inhibition
  • killing
  • MDR TB
  • TDR TB
  • TDR TB cures
  • thioridazine
  • XDR TB

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology

Cite this

@article{b27cb15e314544f0b4ea801f4fc0db16,
title = "Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis",
abstract = "Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible. This article will describe the authors' further work and the mechanisms by which thioridazine alone and in combination with antibiotics cures an extensively drug-resistant infection and why it is expected to cure totally drug-resistant TB infections as well. The concepts presented are entirely new and because they focus on the activation of killing by nonkilling macrophages where M. tuberculosis normally resides during infection, and coupled to the inhibition of efflux pumps which contribute to the antibiotic-resistant status, effective therapy of any antibiotic-resistant TB infection is possible.",
keywords = "efflux pumps, inhibition, killing, MDR TB, TDR TB, TDR TB cures, thioridazine, XDR TB",
author = "Leonard Amaral and J. Moln{\'a}r",
year = "2012",
month = "8",
doi = "10.1586/eri.12.73",
language = "English",
volume = "10",
pages = "869--873",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis

AU - Amaral, Leonard

AU - Molnár, J.

PY - 2012/8

Y1 - 2012/8

N2 - Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible. This article will describe the authors' further work and the mechanisms by which thioridazine alone and in combination with antibiotics cures an extensively drug-resistant infection and why it is expected to cure totally drug-resistant TB infections as well. The concepts presented are entirely new and because they focus on the activation of killing by nonkilling macrophages where M. tuberculosis normally resides during infection, and coupled to the inhibition of efflux pumps which contribute to the antibiotic-resistant status, effective therapy of any antibiotic-resistant TB infection is possible.

AB - Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible. This article will describe the authors' further work and the mechanisms by which thioridazine alone and in combination with antibiotics cures an extensively drug-resistant infection and why it is expected to cure totally drug-resistant TB infections as well. The concepts presented are entirely new and because they focus on the activation of killing by nonkilling macrophages where M. tuberculosis normally resides during infection, and coupled to the inhibition of efflux pumps which contribute to the antibiotic-resistant status, effective therapy of any antibiotic-resistant TB infection is possible.

KW - efflux pumps

KW - inhibition

KW - killing

KW - MDR TB

KW - TDR TB

KW - TDR TB cures

KW - thioridazine

KW - XDR TB

UR - http://www.scopus.com/inward/record.url?scp=84867040746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867040746&partnerID=8YFLogxK

U2 - 10.1586/eri.12.73

DO - 10.1586/eri.12.73

M3 - Article

C2 - 23030326

AN - SCOPUS:84867040746

VL - 10

SP - 869

EP - 873

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 8

ER -